Thema: US38341P2011
GOSS, US38341P2011
stock-5275746_1920.jpg - Foto: THN
Gossamer Bio stock advances seralutinib NDA toward FDA review
Gossamer Bio stock is moving into FDA review after the company submitted its first NDA for seralutinib. Funding remains tied to regulatory acceptance.
ad-hoc-news.de, heute 02:09 Uhr
GOSS, US38341P2011
Gossamer Bio files FDA application. Gossamer Bio stock sits ...
Second-quarter revenue reached USD 9.24 million in Q2 2026. Gossamer Bio stock had a USD 54.3 million market value on October 15, 2026.
ad-hoc-news.de, 16.10.26 05:21 Uhr
GOSS, US38341P2011
Chardan sets USD 160.00 target for Gossamer Bio stock
Chardan's Buy rating names a USD 160.00 target on October 13, 2026. For Gossamer Bio stock, revenue was USD 9.24 million in the second quarter of 2026.
ad-hoc-news.de, 14.10.26 04:58 Uhr
